Pharma-Bio Serv annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Pharma-Bio Serv's gross margin was 32.33% for fiscal 2025.
View full Pharma-Bio Serv company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-10-31 | 32.33% | +5.87 pp |
| 2024 | 2024-10-31 | 26.46% | −3.38 pp |
| 2023 | 2023-10-31 | 29.84% | +4.68 pp |
| 2022 | 2022-10-31 | 25.16% | −1.48 pp |
| 2021 | 2021-10-31 | 26.65% | −4.27 pp |
| 2020 | 2020-10-31 | 30.92% | −0.75 pp |
| 2019 | 2019-10-31 | 31.66% | −0.29 pp |
| 2018 | 2018-10-31 | 31.95% | +3.06 pp |
| 2017 | 2017-10-31 | 28.89% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-04-30 | 33.37% | −0.50 pp |
| Q1 2026 | 2026-01-31 | 31.48% | +0.40 pp |
| Q4 2025 | 2025-10-31 | 34.84% | +3.70 pp |
| Q3 2025 | 2025-07-31 | 29.25% | +2.98 pp |
| Q2 2025 | 2025-04-30 | 33.87% | +7.86 pp |
| Q1 2025 | 2025-01-31 | 31.08% | +8.58 pp |
| Q4 2024 | 2024-10-31 | 31.14% | +5.30 pp |
| Q3 2024 | 2024-07-31 | 26.28% | −7.59 pp |
| Q2 2024 | 2024-04-30 | 26.01% | −3.49 pp |
| Q1 2024 | 2024-01-31 | 22.50% | −6.76 pp |
| Q4 2023 | 2023-10-31 | 25.84% | +1.94 pp |
| Q3 2023 | 2023-07-31 | 33.86% | +6.38 pp |
| Q2 2023 | 2023-04-30 | 29.51% | +5.03 pp |
| Q1 2023 | 2023-01-31 | 29.26% | +4.46 pp |
| Q4 2022 | 2022-10-31 | 23.90% | −2.88 pp |
| Q3 2022 | 2022-07-31 | 27.49% | +2.33 pp |
| Q2 2022 | 2022-04-30 | 24.48% | −1.13 pp |
| Q1 2022 | 2022-01-31 | 24.80% | −4.50 pp |
| Q4 2021 | 2021-10-31 | 26.78% | −0.24 pp |
| Q3 2021 | 2021-07-31 | 25.16% | −4.37 pp |
| Q2 2021 | 2021-04-30 | 25.60% | −7.49 pp |
| Q1 2021 | 2021-01-31 | 29.30% | −5.08 pp |
| Q4 2020 | 2020-10-31 | 27.02% | −4.87 pp |
| Q3 2020 | 2020-07-31 | 29.53% | −2.00 pp |
| Q2 2020 | 2020-04-30 | 33.09% | +2.15 pp |
| Q1 2020 | 2020-01-31 | 34.38% | +1.99 pp |
| Q4 2019 | 2019-10-31 | 31.89% | −1.15 pp |
| Q3 2019 | 2019-07-31 | 31.53% | −2.89 pp |
| Q2 2019 | 2019-04-30 | 30.94% | +3.40 pp |
| Q1 2019 | 2019-01-31 | 32.39% | +0.69 pp |
| Q4 2018 | 2018-10-31 | 33.03% | +9.72 pp |
| Q3 2018 | 2018-07-31 | 34.41% | +7.86 pp |
| Q2 2018 | 2018-04-30 | 27.54% | — |
| Q1 2018 | 2018-01-31 | 31.71% | — |
| Q3 2017 | 2017-07-31 | 23.32% | — |
| Q2 2017 | 2017-04-30 | 26.55% | — |
Over the last five reported fiscal years, Pharma-Bio Serv's gross margin increased from 30.92% to 32.33%, a change of +1.41 percentage points. The latest reported quarter, Q2 2026, shows 33.37%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharma-Bio Serv filings at SEC.gov ↗